PBH Relative Valuation
PBH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PBH is overvalued; if below, it's undervalued.
Historical Valuation
Prestige Consumer Healthcare Inc (PBH) is now in the Overvalued zone, suggesting that its current forward PE ratio of 16.23 is considered Overvalued compared with the five-year average of 14.17. The fair price of Prestige Consumer Healthcare Inc (PBH) is between 60.26 to 73.86 according to relative valuation methord. Compared to the current price of 76.50 USD , Prestige Consumer Healthcare Inc is Overvalued By 3.57%.
Relative Value
Fair Zone
60.26-73.86
Current Price：76.50
3.57%
Overvalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
2.09
P/B
Median3y
2.03
Median5y
1.91
6.27
FCF Yield
Median3y
7.17
Median5y
8.09
Competitors Valuation Multiple
The average P/S ratio for PBH's competitors is 15.83, providing a benchmark for relative valuation. Prestige Consumer Healthcare Inc Corp (PBH) exhibits a P/S ratio of 3.37, which is -78.68% above the industry average. Given its robust revenue growth of 7.05%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Prestige Consumer Healthcare Inc (PBH) currently overvalued or undervalued?
What is Prestige Consumer Healthcare Inc (PBH) fair value?
How does PBH's valuation metrics compare to the industry average?
What is the current P/B ratio for Prestige Consumer Healthcare Inc (PBH) as of Jul 13 2025?
What is the current FCF Yield for Prestige Consumer Healthcare Inc (PBH) as of Jul 13 2025?
What is the current Forward P/E ratio for Prestige Consumer Healthcare Inc (PBH) as of Jul 13 2025?